文献速递妇科肿瘤

晚期卵巢癌新辅助化疗使用倾向与总生存的关联

Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer.
PubMed 文献 · JAMA Oncol · 2021-01-01

该研究利用美国癌症委员会认证项目对新辅助化疗的差异化采纳,对2004-2015年诊断的IIIC/IV期上皮性卵巢癌患者进行双重差分比较效益分析。高使用项目与低使用项目相比,2010年后标准化中位总生存改善幅度相似(差异0.9个月,95%CI -1.9至3.7),但高使用项目1年死亡率下降更大(差异-2.1%,95%CI -3.7至-0.5)。

要点

  • 高与低新辅助化疗使用项目的中位总生存改善相似,差异无统计学意义
  • 高使用项目1年全因死亡率下降幅度更大(差异-2.1%)
  • 新辅助化疗使用增加未损害晚期卵巢癌患者的长期生存

核心结论

  • 与低使用新辅助化疗的癌症项目相比,高使用项目的中位总生存改善相似,但短期死亡率下降更大。

研究设计与样本

  • 双重差分比较效益分析,利用美国癌症委员会认证项目对新辅助化疗的差异化采纳。
  • 纳入2004年1月至2015年12月诊断的IIIC和IV期上皮性卵巢癌女性,随访至2018年底。

主要发现

  • 高使用项目新辅助化疗比例从2004-2009年的21.7%增至2010-2015年的42.2%,低使用项目从20.1%增至22.5%。
  • 高使用项目标准化中位总生存从31.6个月增至37.9个月(差异6.3个月,95%CI 4.2-8.3),低使用项目从31.4个月增至36.8个月(差异5.4个月,95%CI 3.5-7.3)。
  • 双重差分显示总生存改善差异为0.9个月(95%CI -1.9至3.7)。
  • 高使用项目1年死亡率从25.6%降至19.3%(风险差异-5.2%,95%CI -6.4至-4.1),低使用项目从24.9%降至21.8%(风险差异-3.2%,95%CI -4.3至-2.0)。
  • 1年死亡率双重差分风险差异为-2.1%(95%CI -3.7至-0.5)。

临床怎么用

  • 在晚期卵巢癌中增加新辅助化疗使用未导致长期生存受损,且与短期死亡率下降相关。
  • 癌症项目可考虑根据病例组合适当提高新辅助化疗使用比例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Randomized clinical trials have found that, in patients with advanced-stage epithelial ovarian cancer, neoadjuvant chemotherapy has similar long-term survival and improved perioperative outcomes compared with primary cytoreductive surgery. Despite this, considerable controversy remains about the appropriate use of neoadjuvant chemotherapy, and the proportion of patients who receive this treatment varies considerably among cancer programs in the US. OBJECTIVE: To evaluate the association between high levels of neoadjuvant chemotherapy administration and overall survival in patients with advanced ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: This difference-in-differences comparative effectiveness analysis leveraged differential adoption of neoadjuvant chemotherapy in Commission on Cancer-accredited cancer programs in the US and included women with a diagnosis of stage IIIC and IV epithelial ovarian cancer between January 2004 and December 2015 who were followed up through the end of 2018. The data were analyzed between September 2020 and January 2021. EXPOSURES: Treatment in a cancer program with high levels of neoadjuvant chemotherapy administration (more often than expected based on case mix) or in a program that continued to restrict its use after the 2010 publication of a clinical trial demonstrating the noninferiority of neoadjuvant chemotherapy compared with primary surgery for the treatment of patients with advanced ovarian cancer. MAIN OUTCOMES AND MEASURES: Case mix-standardized median overall survival time and 1-year all-cause mortality assessed with a flexible parametric survival model. RESULTS: We identified 19 562 patients (mean [SD] age, 63.9 [12.6] years; 3.2% Asian, 8.0% Black, 4.8% Hispanic, 82.5% White individuals) who were treated in 332 cancer programs that increased use of neoadjuvant chemotherapy from 21.7% in 2004 to 2009 to 42.2% in 2010 to 2015 and 19 737 patients (mean [SD] age, 63.5 [12.6] years; 3.1% Asian, 7.7% Black, 6.5% Hispanic, 81.8% White individuals) who were treated in 332 programs that marginally increased use of neoadjuvant chemotherapy (20.1% to 22.5%) over these periods. The standardized median overall survival times improved by similar magnitudes in programs with high (from 31.6 [IQR, 12.3-70.1] to 37.9 [IQR, 17.0-84.9] months; 6.3-month difference; 95% CI, 4.2-8.3) and low (from 31.4 [IQR, 12.1-67.2] to 36.8 [IQR, 15.0-80.3] months; 5.4-month difference, 95% CI, 3.5-7.3) use of neoadjuvant chemotherapy after 2010 (difference-in-differences, 0.9 months; 95% CI, -1.9 to 3.7). One-year mortality declined more in programs with high (from 25.6% to 19.3%; risk difference, -5.2%; 95% CI, -6.4 to -4.1) than with low (from 24.9% to 21.8%; risk difference, -3.2%, 95% CI, -4.3 to -2.0) use of neoadjuvant chemotherapy (difference-in-differences, -2.1%; 95% CI, -3.7 to -0.5). CONCLUSIONS AND RELEVANCE: In this comparative effectiveness research study, compared with cancer programs with low use of neoadjuvant chemotherapy, those with high use had similar improvements in median overall survival and larger declines in short-term mortality.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Melamed A, Rauh-Hain JA, Gockley AA, et al. Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. JAMA Oncol. 2021. PMID: 34591081. doi:10.1001/jamaoncol.2021.4252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。